fbpx Announcing the Food Allergy Prevention QuickFire Challenge - News | JLABS

Announcing the Food Allergy Prevention QuickFire Challenge

November 16, 2021 -
20 days ago
JLABS in the Media

November 17, 2021 – Together with the Food Allergy Fund, Johnson & Johnson Innovation and the Healthy Baby Initiative within Janssen Research & Development’s World Without Disease Accelerator (WWDA) are proud to launch the Food Allergy Prevention QuickFire Challenge with the aim to identify potential solutions to prevent children from developing food allergy in the early years of their life.

Food allergy is a growing public health problem. For many affected individuals, food allergy begins early in life and persists as a lifelong condition. Research suggests there is a window of opportunity in the early years of a child’s life to reduce the risk of food allergy with early and ongoing ingestion of allergenic foods such as peanut and a diverse diet. In addition, increasing data suggests a critical role for a healthy gut microbiome in decreasing the risk of food allergy. Progress is being made in identifying recognizable risk factors associated with increased likelihood of developing food allergy, including atopic dermatitis, antibiotic exposure, C-section delivery and/or a gut microbiome dysbiosis.

The innovator(s) with the best novel methods, products, or technologies can receive grant funding from a total pool of $150,000, access to the global Johnson & Johnson Innovation – JLABS network, and mentorship from experts across the Johnson & Johnson Family of Companies.*

Apply at jji.jnj/food-allergy by February 18, 2022.

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.

* Subject to the execution of the necessary documentation and (award) agreements.

Camden

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

Camden

About Janssen Research & Development LLC

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Camden

Food Allergy Fund

The Food Allergy Fund is dedicated to funding food allergy research focused on the underlying causes of food allergies and improved treatments for people with food allergies. The Food Allergy Fund enlists celebrity ambassadors, industry partners, and individuals to raise public awareness and to support scientific research


Related content